Quoin Pharmaceuticals, Ltd. - 8-K Filing
Quoin Pharmaceuticals received Orphan Drug Designation from Japan's MHLW for QRX003 lotion in the treatment of Netherton Syndrome, a rare genetic skin disorder. This designation provides regulatory incentives including up to 10 years of market exclusivity upon approval and follows similar designations granted by U.S. FDA and EMA. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $QNRX